PRFX - PainReform Ltd Debt to Book Capitalization Ratio

Graphic logo of PainReform Ltd (PRFX)

PainReform Ltd. develops innovative long-acting analgesics, minimizing opioid dependence through patent protection. This daily chart of the total debt-to-book capitalization ratio on GURU.Markets reflects leverage dynamics, where the value 0.00 serves as the baseline indicator. Production robotization ensures formula precision, while diversified raw material supply chains bolster business resilience.

PRFX (PainReform Corp) Debt to Book Value history from 07/04/2022 to 10/27/2026

PainReform Ltd (PRFX) - metric breakdowns and financial figures

- price and consensus price forecast:
Stock Price PainReform Ltd.|PRFX - Analyst Consensus Forecast
- market capitalization data:
Market Value PainReform Corp|PRFX - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share PainReform|PRFX - Company Net Assets|Market Capitalization to Book Value Ratio painreform.com|PRFX - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio PainReform Ltd.|PRFX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity PainReform Limited|PRFX - Company Cumulative Debt|Debt to Book Value PainReform Corp
Analysis of all company metrics:PRFX PainReform Ltd.
Core merchandise of PainReform Limited

This indicator reflects the share of liabilities within the equity structure of PainReform Ltd. (PRFX). Analyzing this parameter allows investors to decouple market volatility from actual changes in the issuer's financial stability. The trend in the ratio of borrowed funds to capitalization demonstrates the balance between debt load and investment development. A downward trend enhances business reliability but may signal stagnation. For PainReform Ltd. (PRFX), this is critical when scaling sales of analgesic drugs in surgical hospitals.

Competitors of PainReform Ltd.

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|ANIP: Debt to Book Capitalization Ratio|MNKD - Debts to Book Value|Debt to Book Value Amphastar Pharmaceuticals AMPH|PCRX - Debt to Book Capital|Debts to Book Capitalization ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Debt to Net Assets Ratio|Debts to Book Capitalization AQST (Aquestive Pharma)|Debts to Book Value SCPH|Tectonic Therapeutic, Inc. (TECX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio TNXP (tonixpharma.com)|China SXT Pharmaceuticals, Inc. (SXTC) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Eupraxia Pharmaceuticals, Inc. EPRX|BioHarvest - Debts to Book Capitalization|EXOZ - Debts to Book Capitalization|oramed.com - Debts to Book Capitalization|ENTX (Entera Bio) - Debts to Net Assets|Debt to Book Capitalization Ratio MindWalk Holdings Inc. (HYFT)|Debt to Book Value Ratio ABVC|Cumberland Pharma (CPIX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio Quantum BioPharma Corp (QNTM)|FGEN: Debts to Book Capitalization|Debts to Book Value telomirpharma.com TELO|Debts to Book Capitalization Rani Therapeutics Inc|SNYR: Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio RLYB|LEXX (Lexaria Bioscience Corp.) - Debts to Book Value|PULM - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio PTHL|Debt to Book Capitalization Ratio APM (Aptorum Group Limited)|Debt to Book Value Lyra Therapeutics Inc. LYRA|Debt to Book Value Impact BioMedical Inc|TNF Pharmaceuticals Inc. - Debt to Net Assets Ratio|YCBD - Debt to Book Capitalization Ratio|Altamira Therapeutics (CYTO) - Debt to Book Capitalization Ratio|LIPO - Debt to Book Value|OptiNose Inc (OPTN) - Debt to Book Capital|Debts to Book Capitalization Pieris (PIRS)|Debt to Book Value Ratio Procaps Group Corp (PROC)|PTPI (Petros Pharmaceuticals) - Debt to Book Value|Debts to Net Assets QLI (qlsyy.net)|ACELYRIN (SLRN) - Debt to Book Capitalization Ratio|TFF Pharmaceuticals Inc. - Debts to Book Capitalization Ratio